Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24937449 | 1.00 | SORT1 (0.32) | SORT1SMN1; SMN2 | |
| SCHEMBL16996957 | 1.00 | SORT1 (0.32) | SORT1SMN1; SMN2 | |
| SCHEMBL22929061 | 0.77 | PIK3CD (0.35) | — | |
| SCHEMBL4546629 | 0.77 | PIK3CD (0.31) | — | |
| SCHEMBL17404005 | 0.77 | EBP (0.30) | — | |
| SCHEMBL16259061 | 0.76 | CACNA2D1 (0.38) | — | |
| SCHEMBL25098697 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL17918952 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL16996956 | 0.74 | KDM4E (0.32) | SORT1SMN1; SMN2 | |
| SCHEMBL20224770 | 0.74 | KDM4E (0.32) | SORT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | SORT1 4161/4885SMN1; SMN2 3507/4885 |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | CNR2, CNR1, GPR18 | SORT1 4161/4885SMN1; SMN2 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.